Sofloxacin, Daclatasvir why treatment of hepatitis C is effective
At present, the standard protocol for hepatitis C antiviral therapy is pegylated interferon combined with ribavirin, the cure rate is about 50% to 70%. However, interferon is an indirect effect, easily lead to influenza-like symptoms, blood cell reduction, mental disorders, autoimmune diseases, kidney damage and other side effects, some patients with high resistance.
Europe and the United States and other countries in recent years, continuous approval of the sofloxacin, Daclatasvir and many other direct anti-hepatitis C virus drugs, by direct inhibition of HCV protease, Daclatasvir RNA polymerase or other sites of the virus and play a strong inhibition of viral replication Can act on different stages of the HCV replication cycle, increasing the sustained viral response (SVR, equivalent to clinical cure) to 90%.
Sofosbuv (trade name Sovaldi) is a new drug developed for the treatment of chronic hepatitis C, which was approved by the US Food and Drug Administration (FDA) on December 6, 2013, Nikkei European Medicines Agency (EMEA) approved the listing in the EU countries.
Sofloxacin is the first drug to safely and effectively treat certain types of hepatitis C without the need for interferon. Clinical trials have demonstrated that the overall sustained virological response rate (SVR) is 90% for patients with type 1 and 4 hepatitis C, in combination with pegylated interferon and ribavirin; Daclatasvir for type 2 hepatitis C, the drug is associated with ribavirin Of the SVR of 89% -95%; for type 3 hepatitis C, the drug combined with ribavirin SVR 61% -63%. It is worth mentioning that the clinical trial of soflove also contains some hepatitis C patients with cirrhosis, the effect is more significant.
Dacetavir (English name Daclatasvir) is a British and Japanese-listed treatment of hepatitis C drugs, the effect and treatment cycle is more similar with the soflove.